CBL-514 Injection Lipolysis: A Phase 2 Map of the Evidence
CBL-514 is an investigational injection that aims to trigger fat-cell apoptosis in a treated abdominal area. In a 2025 Phase 2 trial of 76 randomized participants, it produced large ultrasound-measured fat-volume losses versus saline while mean body weight stayed flat. This hub maps the design, the 2 mg/cm² dosing, the exact efficacy figures with their shrinking denominators, and the company-reported DYRK1b/caspase mechanism. It also spells out the caveats: single-blind design, sponsor involvement, about 49% non-completion, short follow-up and a mostly female sample. Five deeper explainers are linked for readers who want to go further.
Does CBL-514 really burn fat? Here's what we know
The 2025 Phase 2 CBL-514 trial did not test weight loss. It tested whether an abdominal injection could cut at least 150 mL of subcutaneous fat volume on ultrasound, and 69.6% (16/23) of treated participants got there at 8 weeks versus 0/16 on placebo. But mean body weight did not fall (+0.02 kg), nearly half of treated participants did not complete the study, and the per-protocol group was just 30 people. Injection-site reactions were common, including discoloration in 71.4% and severe pain in 18.4%. Here is the data-first breakdown of what the trial shows and what it doesn't.
How does CBL-514 work? Here's the science
CBL-514 is not framed as a fat-melting or fat-burning drug. The proposed claim is that it inhibits the survival kinase DYRK1b and pushes fat cells toward apoptosis through caspase 3 and Bax/Bcl-2. That evidence comes from unpublished company reports cited in the Phase 2a and Phase 2 papers, and the chemical structure has not been disclosed. The 2025 Phase 2 trial measured ultrasound fat volume, photos, and safety, with no human biopsy or caspase data. This article separates the molecular hypothesis from what was actually measured in people, including the high dropout and single-blind design.